US Orphan Diseases Market

US Orphan Diseases Market Research Report: Size, Share, Trend Analysis By Disease Type (Genetic Disorders, Metabolic Disorders, Neurological Disorders, Immunodeficiency Disorders, Cognitive Disorders), By Treatment Type (Pharmaceuticals, Gene Therapy, Biologics, Enzyme Replacement Therapy, Small Molecule Therapies), By Route of Administration (Oral, Injectable, Intravenous, Topical, Inhalation), By Patient Age Group (Pediatric, Adult, Geriatric) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period
2025 - 2035
CAGR
5.9%
2024 Market Size
$ 41 Billion
2035 Market Size
$ 77 Billion
Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/17466-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Disease Type (USD Billion)
      1. 4.1.1 Genetic Disorders
      2. 4.1.2 Metabolic Disorders
      3. 4.1.3 Neurological Disorders
      4. 4.1.4 Immunodeficiency Disorders
      5. 4.1.5 Cognitive Disorders
    2. 4.2 Food, Beverages & Nutrition, BY Treatment Type (USD Billion)
      1. 4.2.1 Pharmaceuticals
      2. 4.2.2 Gene Therapy
      3. 4.2.3 Biologics
      4. 4.2.4 Enzyme Replacement Therapy
      5. 4.2.5 Small Molecule Therapies
    3. 4.3 Food, Beverages & Nutrition, BY Route of Administration (USD Billion)
      1. 4.3.1 Oral
      2. 4.3.2 Injectable
      3. 4.3.3 Intravenous
      4. 4.3.4 Topical
      5. 4.3.5 Inhalation
    4. 4.4 Food, Beverages & Nutrition, BY Patient Age Group (USD Billion)
      1. 4.4.1 Pediatric
      2. 4.4.2 Adult
      3. 4.4.3 Geriatric
    5. 4.5 Food, Beverages & Nutrition, BY Distribution Channel (USD Billion)
      1. 4.5.1 Hospital Pharmacy
      2. 4.5.2 Retail Pharmacy
      3. 4.5.3 Online Pharmacy
      4. 4.5.4 Specialty Pharmacy
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Vertex Pharmaceuticals (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Biogen (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Amgen (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Novartis (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Roche (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Regeneron Pharmaceuticals (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sarepta Therapeutics (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Alexion Pharmaceuticals (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DISEASE TYPE
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
    6. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    7. 6.7 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    10. 6.10 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    12. 6.12 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY DISEASE TYPE, 2024 (% SHARE)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 (% SHARE)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY PATIENT AGE GROUP, 2024 (% SHARE)
    20. 6.20 FOOD, BEVERAGES & NUTRITION, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Billion)
    21. 6.21 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    22. 6.22 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
      5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1
Share::
WhatsApp icon
LinkedIn icon
X (Twitter) icon
ChatGPT icon
Perplexity icon
Request Free Sample

US Orphan Diseases Market Segmentation

US Orphan Diseases Market By Disease Type (USD Billion, 2025-2035)

  • Genetic Disorders
  • Metabolic Disorders
  • Neurological Disorders
  • Immunodeficiency Disorders
  • Cognitive Disorders

US Orphan Diseases Market By Treatment Type (USD Billion, 2025-2035)

  • US Orphan Diseases Markets
  • Gene Therapy
  • Biologics
  • Enzyme Replacement Therapy
  • Small Molecule Therapies

US Orphan Diseases Market By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Injectable
  • Intravenous
  • Topical
  • Inhalation

US Orphan Diseases Market By Patient Age Group (USD Billion, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

US Orphan Diseases Market By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Specialty Pharmacy
Share::
WhatsApp icon
LinkedIn icon
X (Twitter) icon
ChatGPT icon
Perplexity icon
Request Free Sample

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.